nach oben

Erschienen in:

20.06.2022 | Streptokokken | CME fortbildung

Bakterielle Infektion der Haut

Pathogenese, Klinik und Therapie des Erysipels

verfasst von: Dr. med. univ. Carina Borst, Dr. med. univ. Dörte Symmank

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

Das Erysipel ist eine häufig vorkommende, akut auftretende, bakterielle Infektion der Haut, die oft mit Systemzeichen einhergeht. Diagnostisch ist die Kombination der klassischen klinischen Präsentation und erhöhten Entzündungswerten wegweisend. Nach Antibiotikabehandlung heilt das Erysipel meist komplikationslos ab, allerdings können sich chronisch-rezidivierende Verläufe etablieren. …

Cervellin G et al. One holy man, one eponym, three distinct diseases. St. Anthony's fire revisited. Acta Biomed 2020;92:e2021008

Paladino ME et al. Erysipelas over the centuries: notes from the history of popes. Intern Emerg Med 2021;16:1727-8

Morris AD. Cellulitis and erysipelas. BMJ Clin Evid 2008;2008:1708

Sunderkötter C et al. S2k-Leitlinie Haut- und WeichgewebeinfektionenAuszug aus 'Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018'. J Dtsch Dermatol Ges 2019;17:345-71

Sočan K et al. Trends in the epidemiology of erysipelas in Slovenia. Acta Dermatovenerologica Alpina Pannonica Adriat 2018;27:1-4

Eriksson B et al. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996;23:1091-8

Karakonstantis S. Is coverage of S. aureus necessary in cellulitis/erysipelas? A literature review. Infection 2020;48:183-91

Cho C Y et al. Group B streptococcal infection in neonates and colonization in pregnant women: an epidemiological retrospective analysis. J Microbiol Immunol Infect 2019;52:265-72

Chiller K et al. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc 2001;6:170-4

10.

Metzgar D et al. The M protein of group A streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence 2011;2:402-12

11.

Johansson L et al. Getting under the skin: the immunopathogenesis of streptococcus pyogenes deep tissue infections. Clin Infect Dis 2010;51:58-65

12.

Brishkoska-Boshkovski V et al. Comorbidities as risk factors for acute and recurrent erysipelas. Open Access Maced J Med Sci 2019;7:937-42

13.

Jendoubi F et al. Intracellular streptococcal uptake and persistence: a potential cause of erysipelas recurrence. Front Med 2019;6:6

14.

Gunderson CG et al. A systematic review of bacteremias in cellulitis and erysipelas. J Infect 2012;64:148-55

15.

Duvanel T et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989;149:293-6

16.

Raff AB et al. Cellulitis: a review. JAMA 2016;316:325-37

17.

Ren Z et al. Burden, risk factors, and infectious complications of cellulitis and erysipelas in US adults and children in the emergency department setting. J Am Acad Dermatol 2021;84:1496-503

18.

Drerup C et al. Diagnostic value of laboratory parameters for the discrimination between erysipelas and limited cellulitis. J Dtsch Dermatol Ges 2020;18:1417-24

19.

Brishkoska-Boshkovski V et al. Clinical presentation and laboratory characteristics in acute and recurrent erysipelas. Open Access Maced J Med Sci 2019;7:771-4

20.

Erturk A et al. The association between serum YKL-40 levels, mean platelet volume, and c reactive protein in patients with cellulitis. Indian J Med Microbiol 2015;33:61-6

21.

Pyo JY et al. Delta neutrophil index contributes to the differential diagnosis between acute gout attack and cellulitis within 24 hours after hospitalization. Rheumatology (Oxford) 2017;56:795-801

22.

Noh SH et al. Serum procalcitonin level reflects the severity of cellulitis. Ann Dermatol 2016;28:704-10

23.

Cox NH et al. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006;155:947-50

24.

Mokni M, Dupuy A, Denguezli M et al (2006) Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006;212:108-12

25.

Björnsdóttir S et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005;41:1416-22

26.

Sapuła M et al. In search of risk factors for recurrent erysipelas and cellulitis of the lower limb: a cross-sectional study of epidemiological characteristics of patients hospitalized due to skin and soft-tissue infections. Interdiscip Perspect Infect Dis 2020:1307232

27.

Halpern J et al. Ethnicity and other risk factors for acute lower limb cellulitis: a U.K.-based prospective case-control study. Br J Dermatol 2008;158:1288-92

28.

Musette P et al. Determinants of severity for superficial cellutitis (erysipelas) of the leg: a retrospective study. Eur J Intern Med 2004;15:446-50

29.

Tay EY et al. Cellulitis recurrence score: a tool for predicting recurrence of lower limb cellulitis. J Am Acad Dermatol 2015;72:140-5

30.

Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303:1-10

31.

Hanifin JM et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-8

32.

Fokina EG et al. Prediction degree severity of erysipelas: risk index of hemorrhagic form of erysipelas. J Infect Dis Treat 2016;2:2

33.

Rath E et al. Non-purulent skin and soft tissue infections: predictive power of a severity score and the appropriateness of treatment in a prospective cohort. Infect Dis (Lond) 2020;52:361-71

34.

Marwick C et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother 2011;66:387-97

35.

Ibrahim LF et al. Development and validation of a cellulitis risk score: the melbourne ASSET score. Pediatrics 2019;143:e20181420

36.

Fitch MT et al. Videos in clinical medicine. Abscess incision and drainage. N Engl J Med 2007;357:e20

37.

Anaya DA et al. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007;44:705-10

38.

Goh T et al. Early diagnosis of necrotizing fasciitis. Br J Surg 2014;101:e119-25

39.

Sundaresan S et al. Stasis dermatitis: pathophysiology, evaluation, and management. Am J Clin Dermatol 2017;18:383-390

40.

Leitlinie "Diagnostik und Therapie der Venenthrombose und der Lungenembolie". 2019, AWMF-Registernummer 065/002

41.

Olson SA et al. Acute compartment syndrome in lower extremity musculoskeletal trauma. J Am Acad Orthop Surg 2005;13:436-44

42.

Vandersee S. Erysipelas carcinomatosum. Dtsch Arztebl Int 2019;116:22

43.

Figueras-Nart I et al. Dermatologic and dermatopathologic features of monogenic autoinflammatory diseases. Front Immunol 2019;10:2448

44.

Eder S et al. Is compression therapy contraindicated for lower leg erysipelas? : results of a retrospective analysis. Hautarzt 2021;72:34-41

45.

Johnson S et al. Can cycloidal vibration plus standard treatment reduce lower limb cellulitis treatment times? J Wound Care 2007;16:166-9

Titel: Bakterielle Infektion der Haut
Pathogenese, Klinik und Therapie des Erysipels
verfasst von: Dr. med. univ. Carina Borst
Dr. med. univ. Dörte Symmank
Publikationsdatum: 20.06.2022
Verlag: Springer Medizin
Schlagwörter: Streptokokken
Phlegmone
Erysipel
Ästhetische Chirurgie
Ästhetische Dermatologie
Ästhetisch-Plastische Chirurgie
Erschienen in: ästhetische dermatologie & kosmetologie / Ausgabe 3/2022
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI: https://doi.org/10.1007/s12634-022-1667-5

Feuchtigkeitsspendende Hautreinigung

Neues aus der Industrie

adk Beitrittsantrag

Radiofrequenz-Microneedling: eine Lösung bei Rosazea?

Rosazea
Redaktionstipp

JAK-Inhibitor bei atopischer Dermatitis

Atopische Dermatitis
Neues aus der Industrie

Vielseitigere Behandlungsmöglichkeiten

Nävi
Neues aus der Industrie

Ästhetik in der Pandemie

Botulinumtoxin
Newsmix